COMPANY PROFILE

JHL Biotech

Develops biosimilars and accelerates the development programs of distinguished clients and partners through the provision of contract development and manufacturing services

TaiwanFounded 2012Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2018

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About JHL Biotech

JHL Biotech is a Contract Development and Manufacturing Organization (CDMO) that specializes in the development and production of biologics, including biosimilars. The company operates in the global healthcare market, focusing on increasing the availability of biotechnology medicines. JHL Biotech serves pharmaceutical and biotechnology companies by providing comprehensive services from cell line development to cGMP manufacturing and regulatory affairs. The business model revolves around offering end-to-end solutions for biologics development, which allows clients to bring their products to market efficiently and cost-effectively. Revenue is generated through service contracts and long-term partnerships with clients. The company has a strong presence in Taiwan and China, with facilities designed to meet global regulatory standards. JHL Biotech aims to improve global healthcare by making high-quality biologics more accessible.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2012
Headquarters: Taiwan
Employees: 68
Open positions: None listed
Dealroom signal: 60.9/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Health Diagnostics, Biotech and Pharma, Hard Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Oct 2018	$0	$750M	Sanofi	—
CONVERTIBLEOther financing	May 2018	$106M	—	Kleiner Perkins	—

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

JHL Biotech website traffic

Latest recorded traffic for JHL Biotech is 0 monthly website visits, down 100% over the last three months. JHL Biotech's team grew 0% over the past year.

Latest monthly visits0 3-month web change-100% 1-year team growth0%

Monthly website visitsDec 2018–Mar 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BIBivisionA biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT)	Jing'an District, China	Operational	—	$96M	$220M
PRPrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy	Jette, Belgium	Operational
TSTTG Imaging SolutionsPartner for nuclear medicine and molecular imaging solutions that include equipment sales, nationwide service, parts, turnkey diagnostic imaging, and radiopharmaceuticals	Pittsburgh, United States	Acquired
ETEvergreen TheragnosticsContract development and manufacturing of therapeutic radiopharmaceuticals	Jersey City, United States	Acquired
ZHZio HealthPocket-sized biosensor technology for point-of-care molecular testing	London, United Kingdom	Operational
EXExonateTopical small-molecule therapeutics for retinal vascular diseases	Cambridge, United Kingdom	Operational
LILifebrainLong-term investment focus in the laboratory diagnostics sector	Rome, Italy	Acquired
LBLeukos BiotechNew treatments for Acute Myeloid Leukaemia and other haematological malignancies	Barcelona, Spain	Operational